Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

2.5K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.5K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.0K
Cancer Vaccines01:30

Cancer Vaccines

1.3K
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
1.3K
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

820
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates...
820

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Functional screening of TCR-like antibodies using STAR-T cell library for cancer immunotherapy.

EMBO molecular medicine·2026
Same author

Targeting tumor-specific T cells with LAG3-directed interleukin-2 prevents T-cell exhaustion and reinvigorates antitumor immunity.

Signal transduction and targeted therapy·2026
Same author

Fueling the fire: aspartate deficiency primes and fuels STING activation.

The Journal of clinical investigation·2026
Same author

IL-12 augments adoptive cell therapy by reshaping CD8<sup>+</sup> T dynamics and broadening antitumor immunity.

Cancer letters·2026
Same author

Selective elimination of circulating effector CD8 T cells via LTβR blockade separates anti-CD137 efficacy from toxicity.

Science advances·2026
Same author

Reprogramming the tumor microenvironment with antibody against membrane-proximal AXL to overcome immune checkpoint blockade resistance.

Signal transduction and targeted therapy·2026

Related Experiment Video

Updated: May 2, 2026

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
14:20

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

17.8K

Anti-HER2/Neu passive-aggressive immunotherapy.

Eric D Mortenson1, Yang-Xin Fu2

  • 1Department of Melanoma Medical Oncology-Research; MD Anderson Cancer Center; Houston, TX USA.

Oncoimmunology
|March 8, 2014
PubMed
Summary

Adaptive immunity, including CD8+ T cells and CD4+ T cells, is crucial for effective anti-HER2/Neu cancer immunotherapy. CD40/CD40L signaling within the tumor microenvironment is also essential for treatment efficacy.

Keywords:
CD4CD40CD40LCD8HER2Herceptinadaptive immunityantibodyimmunotherapyneu

More Related Videos

High-Content Screening Assay for the Identification of Antibody-Dependent Cellular Cytotoxicity Modifying Compounds
13:59

High-Content Screening Assay for the Identification of Antibody-Dependent Cellular Cytotoxicity Modifying Compounds

Published on: August 18, 2023

3.0K
Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery
13:19

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Published on: April 26, 2024

4.2K

Related Experiment Videos

Last Updated: May 2, 2026

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
14:20

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

17.8K
High-Content Screening Assay for the Identification of Antibody-Dependent Cellular Cytotoxicity Modifying Compounds
13:59

High-Content Screening Assay for the Identification of Antibody-Dependent Cellular Cytotoxicity Modifying Compounds

Published on: August 18, 2023

3.0K
Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery
13:19

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Published on: April 26, 2024

4.2K

Area of Science:

  • Immunology
  • Oncology
  • Cancer Research

Background:

  • Preclinical studies show CD8+ T cells are vital for anti-HER2/Neu immunotherapy.
  • The role of CD4+ T cells and tumor microenvironment signaling in this therapy was less understood.

Purpose of the Study:

  • To investigate the necessity of CD4+ T cells and CD40/CD40L signaling for anti-HER2/Neu therapy efficacy.
  • To further elucidate the role of adaptive immunity in targeted anticancer treatments.

Main Methods:

  • Utilized preclinical models to assess the impact of depleting CD4+ T cells on anti-HER2/Neu therapy.
  • Examined the requirement of CD40/CD40L signaling within the tumor microenvironment during therapy.

Main Results:

  • Confirmed that anti-HER2/Neu therapy requires both CD8+ and CD4+ T cells for optimal efficacy.
  • Demonstrated that CD40/CD40L signaling within the tumor microenvironment is essential for successful anti-HER2/Neu treatment.
  • Highlighted the critical role of adaptive immunity in the effectiveness of targeted cancer therapies.

Conclusions:

  • Adaptive immune responses, involving both CD4+ and CD8+ T cells, are indispensable for anti-HER2/Neu immunotherapy.
  • CD40/CD40L pathway activation in the tumor microenvironment is a key mechanism for effective targeted cancer therapy.